New Biopharmaceuticals - A review of new biologic drug approvals over the years, featuring highlights from 2010 and 2011. - BioPharm International

ADVERTISEMENT

New Biopharmaceuticals
A review of new biologic drug approvals over the years, featuring highlights from 2010 and 2011.


BioPharm International
Volume 25, Issue 6, pp. 34-38

FUSION PRODUCTS

Of the four fusion products approved, two are Fc-fusion based (Eylea and Nulojix) with the antibody Fc portion of the products serving to extend the serum half life of the overall molecule. Nulojix, used to prevent organ rejection following kidney transplant, is interesting in that it evolved from Orneca, which was approved in 2005 for the treatment of rheumatoid arthritis. Orneca negatively regulates the activation of a range of T lymphocytes. Nulojix is a protein engineered version of Orneca, identified through mutagenesis and screening, which binds with greater avidity to a range of T lymphocytes. This engineering apparently underpins a more potent immunosuppresive effect.

Eylea and Nulojix join several previously approved Fc fusion products. The additional two fusion products (Elonva and Provenge) are more novel in this context. Elonva, used to achieve controlled ovarian stimulation in some fertility treatments, is a modified recombinant human follicle stimulating hormone (FSH) in which the carboxy-terminal peptide of the β subunit of human chorionic gonadotropin (hCG) is fused to the FSH β chain. The resulting fusion product retains its ovarian stimulation activity, but displays an improved blood elimination half life.

Provenge, used to treat hormone-refractory prostate cancer, is a more complex product in that it consists of twin active components: autologous antigen-presenting dendritic cells and the recombinant fusion protein, PAP-GM-CSF. The latter consists of human prostatic acid phosphatase (PAP), an antigen expressed in some 95% of prostate cancer tissue, linked to human granulocyte-macrophage colony-stimulating factor (GM–CSF) through a dipeptide (glycine-serine) linker sequence. The treatment approach consists of three phases: an initial collection of dendritic cells from the blood of the prostate cancer patient (dendritic cells are the only antigen-presenting cells that can prime native T lymphocytes to initiate an immune response); in vitro exposure of the collected cells to the fusion product, which results in their activation (the GM–CSF portion of the protein helps to target the PAP protein to the dendritic cells and activate those cells; the PAP portion provides the tumor specificity that will eventually direct the immune system to target prostate cancer) and the final phase, that is, the re-infusion of the activated cells back into the original donor patient.

CONJUGATED PRODUCTS

In addition to Adcetris (described earlier), two additional products approved throughout 2010 and 2011 are engineered using an in vitro conjugation process post protein synthesis. In both instances, the purpose of conjugation is to extend product serum half life. Krystexxal (a recombinant urate oxidase enzyme used to treat gout) is PEGylated with a 10kDa monomethoxy-polyethylene glycol (m-PEG) moiety whereas Victoza (used to treat type 2 diabetes) consists of glucagon like peptide 1 to which a C-14 fatty acid is conjugated.

MARKET VALUE

Although the cumulative biopharmaceutical market value for 2011 is not readily available as yet, cumulative global sales of recombinant therapeutic proteins reached a notable milestone in 2010 (5). In that year, recombinant proteins surpassed the $100 billion mark, reaching an estimated $107 billion. Moreover, that same year 30 individual biopharmaceutical products recorded sales of more than $1 billion each, with Enbrel (etanercept) retaining the top spot and boasting sales value of almost $7.3 billion (5).

In terms of APIs, 2010 figures equate to approximately 21 metric tons (21,000 kg) of pure protein product. Almost two-thirds of that amount—approximately 13.5 tons—is produced in microbial systems (mainly insulin) with the remaining third being produced almost exclusively using animal cell culture (mainly mAbs) (6).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here